{"Clinical Trial ID": "NCT01091168", "Intervention": ["INTERVENTION 1:", "- Vinflunine", "Patients randomized to arm A received a dose of VFL of 280 mg/m2 on day 1 of each cycle every 3 weeks during an intravenous infusion (IV) of 20 minutes. Cycles were repeated every 3 weeks.", "Vinflunine: 280 mg/m2 on day 1 of each cycle every 3 weeks", "INTERVENTION 2:", "- Alkylant agent", "The patients randomized to the control arm (arm B) received an alkylant agent used as a single agent that was available in the research centre and was approved for cancer treatment in the country.", "- Alkylant of the doctor's choice registered in cancer: cyclophosphamide or melphalan or mitomycin C or thiotepa or cisplatin or carboplatin"], "Eligibility": ["\u2022 Inclusion criteria: (main conditions)", "In women between the ages of 18 and 75 with histologically confirmed metastatic/cytologically confirmed breast cancer who cannot afford curative surgery or radiation therapy and who have received at least two previous chemotherapys, including anthracyclines, taxanes, antimetabolites and vinca-alkaloids, and who are no longer candidates for these medicines,", "A Karnofsky performance score of at least 70%, adequate haematological, hepatic and renal functions, and ECG without clinically significant abnormalities.", "- Exclusion criteria:", "\u2022 Concurrent serious medical disorder uncontrolled,", "known or clinical evidence of brain metastasis or leptomenal involvement,", "- Pulmonary lymphangitis or symptomatic pleural effusion or symptomatic ascitis,", "History of the second primary malignancy,", "\u2022 HIV infection, pre-existing neuropathy,", "* Pregnancy or lactation."], "Results": ["Performance measures:", "Overall survival", "For patients who have not died, the survival period will be censored on the date of the last contact or follow-up or on the date of the last news.", "Time limit: from base up to 3 years 1 month", "Results 1:", "Title of the arm/group: Vinflunine", "Description of the arm/group: Patients randomized in the test arm (arm A) received LSV at a dose of 280 mg/m on day 1 of each cycle every 3 weeks during a 20-minute intravenous (IV) infusion.", "Vinflunine: 280 mg/m2 on day 1 of each cycle every 3 weeks", "Total number of participants analysed: 298", "Median (95% confidence interval)", "Unit of measure: Month 9.1 (7.7-10.4)", "Results 2:", "Title of the arm/group: Alkylant agent", "The arm/group description: Randomized patients in the control arm (arm B) received an alkylant agent used as a single agent that was available in the research centre and was approved for cancer treatment in the country.", "- Alkylant of the doctor's choice registered in cancer: cyclophosphamide or melphalan or mitomycin C or thiotepa or cisplatin or carboplatin", "Total number of participants analysed: 296", "Median (95% confidence interval)", "Unit of measure: Month 9.3 (7.5-10.9)"], "Adverse Events": ["Undesirable Events 1:", "Total: 82/297 (27.61 per cent)", "Neutropenia 6/297 (2.02%)", "Anemia 6/297 (2.02%)", "Febrile neutropenia 3/297 (1.01%)", "Thrombocytopenia 1/297 (0.34%)", "- Staphylococcal endocardititis 1/297 (0.34%)", "- Coronary arteriospasm 1/297 (0.34%)", "Atrial fibrillation 1/297 (0.34%)", "Heart failure 0/297 (0.00 %)", "Constipation 5/297 (1.68 per cent)", "Vomiting 6/297 (2.02%)", "Abdominal pain 4/297 (1.35%)", "Adverse Events 2:", "Total: 66/290 (22.76 per cent)", "Neutropenia 0/290 (0.00 %)", "Anemia 0/290 (0.00 %)", "Febrile neutropenia 1/290 (0.34%)", "Thrombocytopenia 2/290 (0.69%)", "- Staphylococcal endocardititis 0/290 (0.00 %)", "- Coronary arteriospasm 0/290 (0.00 %)", "Atrial fibrillation 1/290 (0.34%)", "- Heart failure 1/290 (0.34%)", "- Constipation 0/290 (0.00 %)", "3/290 (1.03%)", "Abdominal pain 1/290 (0.34%)"]}